Overview
Pancragen is a synthetic tetrapeptide bioregulator with the sequence Lys-Glu-Asp-Trp, developed within the Khavinson peptide program as a pancreas-targeted signaling peptide. It is marketed around pancreatic health and blood sugar regulation, but most published work comes from Russian or Khavinson-affiliated groups. That matters for users because the evidence base is not comparable to modern diabetes drugs or FDA-reviewed metabolic therapies.
The proposed mechanism follows the broader short-peptide bioregulator model: very small peptides may enter cells, interact with DNA or histone-associated regulatory regions, and influence protein synthesis in tissue-specific contexts. For Pancragen, the research focus is pancreatic beta-cell function, insulin secretion, glucose tolerance, and oxidative stress in diabetic or aged models. These mechanisms remain investigational and should not be treated as proven clinical effects.
Pancragen is not FDA-approved and has no FDA-approved dosing, indication, label, or quality standard in the United States. It should not replace glucose monitoring, prescribed diabetes medication, diet, exercise, or standard medical care. People using insulin, sulfonylureas, GLP-1 drugs, or SGLT2 inhibitors have a higher practical safety concern because any glucose-active product can complicate hypoglycemia risk.
This guide translates the thin Pancragen literature into practical language: what the compound is, how the bioregulator hypothesis is supposed to work, where the evidence is weakest, what side effects are plausible, and how to think cautiously about sourcing, monitoring, and interactions.
Quick facts
- Mechanism
- Pancreas-targeted short peptide bioregulator
- Primary use
- Pancreatic and glucose metabolism research
- Evidence
- limited
- FDA
- Not approved
- Route
- Oral capsules or research injection
- Typical results
- Subtle metabolic changes reported over weeks in limited studies
Chemical information
Pancragen is a tetrapeptide with the sequence Lys-Glu-Asp-Trp and molecular mass of 576.25 g/mol. Its formula is C26H36N6O9, making it a very small peptide compared with injectable metabolic hormones.
How Pancragen works
Pancragen is proposed to work through peptide-mediated regulation of gene expression rather than through a classic receptor agonist model. The Khavinson framework suggests that short peptides can enter cells and influence transcriptional programs tied to tissue maintenance. In pancreatic models, that hypothesis is applied to beta-cell function, insulin handling, and stress responses. The mechanism is biologically plausible as a research idea, but it is not validated to the standard expected for approved metabolic therapy.
The KEDW sequence is described as a pancreas-associated tetrapeptide. Preclinical reports have evaluated glucose, insulin, and pancreatic tissue markers in diabetic or aged animals, with some reports suggesting improved glucose handling. These findings should be read cautiously because many studies are not independently replicated and often lack the trial design, blinding, and sample sizes expected for clinical decision-making.
Short-peptide bioregulator papers often describe interactions with DNA, histones, methylation status, and transcriptional availability. For users, the practical takeaway is that Pancragen is not a rapid glucose-lowering drug like insulin and is not a GLP-1 receptor agonist. Any expected effect, if present, would likely be gradual and indirect, and should be tracked with objective labs rather than subjective energy or appetite changes.
The biggest unknown is translation to humans. There is no robust FDA-style pharmacology package, no large randomized diabetes trial, and no established biomarker showing that Pancragen selectively reaches human pancreatic tissue after oral or injectable use. That uncertainty should shape every decision about dosing, stacking, and monitoring.
- Short-peptide signaling: Proposed to influence transcriptional activity rather than directly replacing hormones
- Pancreatic focus: Marketed and studied around beta-cell function, insulin secretion, and glucose tolerance
- Slow onset model: Expected effects, if real, would likely emerge over weeks rather than hours
- Indirect metabolic support: Not a substitute for insulin, GLP-1 therapy, metformin, or monitored diabetes care
- Limited replication: Most supportive evidence comes from Russian or Khavinson-linked publications
- Monitoring dependent: Glucose, A1c, and medication changes matter more than subjective wellness reports
Pharmacokinetics
No reliable human pharmacokinetic profile for Pancragen was found in FDA labeling or major Western clinical literature. Any claims about half-life, tissue targeting, or oral bioavailability should be treated as unverified unless tied to a specific tested formulation.
| Parameter | Value | Significance |
|---|---|---|
| Human half-life | Not established | No dependable dosing interval can be inferred |
| Oral absorption | Unknown | Capsule products may not reflect injectable research material |
| Metabolism | Likely peptidase degradation | Expected pathway for a small peptide, but not formally quantified |
| Distribution | Not proven in humans | Pancreas targeting is a hypothesis, not a verified PK fact |
| Onset | Weeks in bioregulator protocols | Not suitable for acute glucose correction |
| Monitoring markers | Glucose, A1c, insulin, C-peptide | Objective labs are needed to judge any metabolic effect |
Dosing & administration
There is no FDA-approved Pancragen dose. Commercial bioregulator protocols often use oral capsule courses, while research vendors may sell lyophilized material for laboratory use. Those practices should not be confused with clinically validated dosing.
For peptide users, the cautious approach is to avoid changing diabetes medications around Pancragen without clinician oversight. Any glucose-active intervention should be paired with home glucose tracking and periodic lab review, especially in people using insulin or insulin secretagogues.
Because human PK and long-term safety are not established, stacking Pancragen with multiple metabolic peptides makes interpretation difficult. Combining it with GLP-1 drugs, berberine, metformin, or fasting protocols may increase uncertainty around appetite, glucose, and hypoglycemia symptoms.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Pancragen should be treated as investigational outside jurisdictions where a specific product is lawfully marketed. The main safety issue is not a known toxicity signal but the absence of high-quality human data, plus the risk of using it in place of evidence-based diabetes treatment.
Common
- • Mild stomach upset
- • Headache
- • Injection site redness if injected
- • Transient fatigue
- • Unclear glucose changes
- • Taste or reflux complaints with oral products
Serious / potential risks
- • Hypoglycemia risk if combined with glucose-lowering drugs
- • Allergic reaction to peptide or excipients
- • Worsening glucose control if used instead of standard care
- • Contamination or mislabeling from unregulated suppliers
- • Unknown long-term pancreatic effects in humans
Drug interactions
Drug interaction data are not formally established; the following concerns are theoretical and based on the compound's metabolic positioning.
| Medication | Interaction | Recommendation |
|---|---|---|
| Insulin | Possible additive glucose-lowering uncertainty | Use only with medical supervision and glucose monitoring |
| Sulfonylureas | Hypoglycemia risk may be harder to predict | Avoid unsupervised combinations |
| GLP-1 receptor agonists | Overlapping metabolic goals but different mechanisms | Track appetite, glucose, and GI effects |
| Metformin | Potential overlap in glucose-control endpoints | Monitor glucose trends rather than symptoms alone |
| Corticosteroids | Steroids may raise glucose and mask interpretation | Use lab-based monitoring |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Bioregulator capsule suppliers | Variable, often sold as monthly courses | Product identity and peptide content can vary |
| Research peptide vendors | No standardized medical pricing | Research-use material is not approved for human use |
| Clinical longevity practices | Often bundled into programs | Ask for certificate of analysis and monitoring plan |
The bottom line
Pancragen is a pancreas-oriented Khavinson tetrapeptide with an interesting but thin evidence base. It is not an approved diabetes treatment, has no established human PK, and should be evaluated with objective glucose markers if studied at all. The practical stance is cautious curiosity, not substitution for standard metabolic care.
Best for
- • Researchers studying short-peptide bioregulation
- • Users who can track glucose and labs objectively
- • People evaluating pancreas-support claims cautiously
- • Clinician-supervised metabolic experiments
Not for
- • Replacing diabetes medication
- • Unsupervised use with insulin or sulfonylureas
- • Pregnancy or breastfeeding
- • Anyone expecting rapid glucose correction
Related compounds
Phenibut
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Phenibut FAA
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Phenylpiracetam
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Pielotax
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Frequently asked questions
References
- [1] Khavinson VKh, Korkushko OV, Shatilo VB, et al.. Prospects of using pancragen for correction of pancreatic function in elderly people. Bulletin of Experimental Biology and Medicine (2011).
- [2] Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules (2021). doi: 10.3390/molecules26227053 PMID: 34834147
- [3] Khavinson V, Linkova N, Diatlova A, Trofimova S. Peptide Regulation of Cell Differentiation. Stem Cell Reviews and Reports (2020). doi: 10.1007/s12015-019-09938-8 PMID: 31808038
- [4] Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology (2010). doi: 10.1007/s10522-009-9249-8 PMID: 19830585
- [5] American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes. Diabetes Care (2024).
- [6] National Institute of Diabetes and Digestive and Kidney Diseases. Insulin, Medicines, and Other Diabetes Treatments. NIDDK (2024).